These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 28705683)

  • 21. ACVR1-Fc suppresses BMP signaling and chondro-osseous differentiation in an in vitro model of Fibrodysplasia ossificans progressiva.
    Pang J; Zuo Y; Chen Y; Song L; Zhu Q; Yu J; Shan C; Cai Z; Hao J; Kaplan FS; Shore EM; Zhang K
    Bone; 2016 Nov; 92():29-36. PubMed ID: 27492611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osteogenic differentiation of periodontal ligament fibroblasts inhibits osteoclast formation.
    Prins CM; Ceylan M; Hogervorst JMA; Jansen IDC; Schimmel IM; Schoenmaker T; de Vries TJ
    Eur J Cell Biol; 2024 Sep; 103(3):151440. PubMed ID: 38954934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.
    Culbert AL; Chakkalakal SA; Theosmy EG; Brennan TA; Kaplan FS; Shore EM
    Stem Cells; 2014 May; 32(5):1289-300. PubMed ID: 24449086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dysregulated BMP signaling through ACVR1 impairs digit joint development in fibrodysplasia ossificans progressiva (FOP).
    Towler OW; Peck SH; Kaplan FS; Shore EM
    Dev Biol; 2021 Feb; 470():136-146. PubMed ID: 33217406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary cilia mediate skeletogenic BMP and Hedgehog signaling in heterotopic ossification.
    He K; Jiang H; Li W; Toutounchi S; Huang Y; Wu J; Ma X; Baehr W; Pignolo RJ; Ling K; Zhou X; Wang H; Hu J
    Sci Transl Med; 2024 Jul; 16(757):eabn3486. PubMed ID: 39047114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An anti-ACVR1 antibody exacerbates heterotopic ossification by fibro-adipogenic progenitors in fibrodysplasia ossificans progressiva mice.
    Lees-Shepard JB; Stoessel SJ; Chandler JT; Bouchard K; Bento P; Apuzzo LN; Devarakonda PM; Hunter JW; Goldhamer DJ
    J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35503416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva.
    Song GA; Kim HJ; Woo KM; Baek JH; Kim GS; Choi JY; Ryoo HM
    J Biol Chem; 2010 Jul; 285(29):22542-53. PubMed ID: 20463014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.
    Chakkalakal SA; Shore EM
    Methods Mol Biol; 2019; 1891():247-255. PubMed ID: 30414138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transcriptomic Differences Underlying the Activin-A Induced Large Osteoclast Formation in Both Healthy Control and Fibrodysplasia Ossificans Progressiva Osteoclasts.
    Schoenmaker T; Zwaak J; Loos BG; Volckmann R; Koster J; Eekhoff EMW; de Vries TJ
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Fibrodysplasia Ossificans Progressiva (FOP) mutation p.R206H in ACVR1 confers an altered ligand response.
    Hildebrand L; Stange K; Deichsel A; Gossen M; Seemann P
    Cell Signal; 2017 Jan; 29():23-30. PubMed ID: 27713089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induced Pluripotent Stem Cells to Model Human Fibrodysplasia Ossificans Progressiva.
    Cai J; Orlova VV; Cai X; Eekhoff EMW; Zhang K; Pei D; Pan G; Mummery CL; Ten Dijke P
    Stem Cell Reports; 2015 Dec; 5(6):963-970. PubMed ID: 26626181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-throughput screening for modulators of ACVR1 transcription: discovery of potential therapeutics for fibrodysplasia ossificans progressiva.
    Cappato S; Tonachini L; Giacopelli F; Tirone M; Galietta LJ; Sormani M; Giovenzana A; Spinelli AE; Canciani B; Brunelli S; Ravazzolo R; Bocciardi R
    Dis Model Mech; 2016 Jun; 9(6):685-96. PubMed ID: 27125279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The serum levels of activin A and bone morphogenetic protein-4 and -6 in patients with fibrodysplasia ossificans progressiva.
    Ye Z; Wang S; Shan C; Zhu Q; Xue Y; Zhang K
    Orphanet J Rare Dis; 2023 May; 18(1):111. PubMed ID: 37165433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibrodysplasia ossificans progressiva (FOP), a disorder of ectopic osteogenesis, misregulates cell surface expression and trafficking of BMPRIA.
    de la Peña LS; Billings PC; Fiori JL; Ahn J; Kaplan FS; Shore EM
    J Bone Miner Res; 2005 Jul; 20(7):1168-76. PubMed ID: 15940369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.
    Gao P; Inada Y; Hotta A; Sakurai H; Ikeya M
    Stem Cell Res Ther; 2024 Mar; 15(1):83. PubMed ID: 38500216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva.
    Chakkalakal SA; Zhang D; Culbert AL; Convente MR; Caron RJ; Wright AC; Maidment AD; Kaplan FS; Shore EM
    J Bone Miner Res; 2012 Aug; 27(8):1746-56. PubMed ID: 22508565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular Hypoxia Promotes Heterotopic Ossification by Amplifying BMP Signaling.
    Wang H; Lindborg C; Lounev V; Kim JH; McCarrick-Walmsley R; Xu M; Mangiavini L; Groppe JC; Shore EM; Schipani E; Kaplan FS; Pignolo RJ
    J Bone Miner Res; 2016 Sep; 31(9):1652-65. PubMed ID: 27027798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.
    Hatsell SJ; Idone V; Wolken DM; Huang L; Kim HJ; Wang L; Wen X; Nannuru KC; Jimenez J; Xie L; Das N; Makhoul G; Chernomorsky R; D'Ambrosio D; Corpina RA; Schoenherr CJ; Feeley K; Yu PB; Yancopoulos GD; Murphy AJ; Economides AN
    Sci Transl Med; 2015 Sep; 7(303):303ra137. PubMed ID: 26333933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva.
    Hino K; Horigome K; Nishio M; Komura S; Nagata S; Zhao C; Jin Y; Kawakami K; Yamada Y; Ohta A; Toguchida J; Ikeya M
    J Clin Invest; 2017 Sep; 127(9):3339-3352. PubMed ID: 28758906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification.
    Dey D; Bagarova J; Hatsell SJ; Armstrong KA; Huang L; Ermann J; Vonner AJ; Shen Y; Mohedas AH; Lee A; Eekhoff EM; van Schie A; Demay MB; Keller C; Wagers AJ; Economides AN; Yu PB
    Sci Transl Med; 2016 Nov; 8(366):366ra163. PubMed ID: 27881824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.